<DOC>
	<DOCNO>NCT00567697</DOCNO>
	<brief_summary>A prospective multicenter study compare patient CRVO amd secondary macular edema treat ranibizumab versus sham . Safety efficacy evaluate . Patients randomize 1:1 ratio one two arm . 32 patient , 6 month follow . There monthly visit injection first three month subsequently new injection present edema .</brief_summary>
	<brief_title>A Randomized Study Comparing Ranibizumab Sham Patients With Macular Edema Secondary CRVO</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Male female ≥ 50 year 2 . Patients findings consistent CRVO 3 . Patients history decrease visual acuity ≤ 6 month 4 . Patients best correct visual acuity ( BCVA ) letter score study eye ≤ 73 ( 4 distance ) ≥ 6 ( 1 distance ) use ETDRS chart 5 . Patients macular edema verify OCT 6 . Patients macular edema study eye follow characteristic determine fluorescein angiography : secondary noniscemic CRVO define nonperfusion &lt; 10 DA OR secondary ischemic CRVO define nonperfusion &gt; 10 DA 7 . Willing able give write informed consent willing able comply study procedures 8 . Ability cooperate photo OCT examinations 1 . Neovascularisations study eye baseline 2 . Previous treatment participation clinical trial ( either eye ) involve antiangiogenics drug 3 . Use investigational drug 4 . Prior treatment study eye verteporfin , externalbeam radiation therapy , subfoveal laser photocoagulation , vitrectomy , transpupillary thermotherapy . 5 . History submacular surgery study eye , glaucoma filtration , corneal transplantation surgery 6 . Previous current intravitreal subTenon drug delivery study eye 7 . Laserphotocoagulation ( juxtafoveal extrafoveal ) study eye within one month precede Baseline 8 . Extracapsular extraction cataract phacoemulcification within three month precede Baseline , history postcomplications within last 12 month precede Baseline study eye ( uveitis , cyclitis etc ) 9 . History uncontrolled glaucoma study eye ( defined intraocular pressure ≥ 25 mmHg despite treatment antiglaucoma medication ) 10 . Previous violation posterior capsule study eye unless occurred result YAG laser posterior capsulotomy assosiation prior , posterior chamber lens implantation 11 . Afakia absence posterior capsule study eye 12 . Active intraocular inflammation study eye 13 . Any active infection involve ocular adnexa include infectious conjunctivitis , keratitis , scleritis , endophthalmitis , well ideopathic autoimmuneassociated uveitis either eye 14 . Vitreous hemorrhage history og rhegmatogenous retinal detachment macular hole study eye 15 . Any current intraocular condition study eye ( cataract diabetic retinopathia ) opinion investigator , could either require medical surgical intervention study period next 6 month 16 . Ocular condition require chronic concomitant therapy systemic topical ocular corticosteroid . 17 . Current treatment active systemic infection . 18 . Current use likely need systemic medication know toxic lens , retina optic nerve . 19 . History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication 20 . History hypersensitivity allergy fluorescein 21 . Inability obtain fundus photograph fluorescein angiograms sufficient quality analyze 22 . Pregnant nursing ( lactate ) woman 23 . Premenopausal woman childbearing potential use adequate contraception . 24 . History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrance metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>ranibizumab</keyword>
	<keyword>CRVO</keyword>
	<keyword>macular edema</keyword>
	<keyword>sham</keyword>
</DOC>